Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741
about
A new standard of care for the management of peritoneal surface malignancyCell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer CellsA Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal CancerA Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal CancerPulmonary metastasectomy for colorectal cancer: how many nodules, how many times?Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancerAflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.Response to stress in early tumor colonization modulates switching of CD133-positive and CD133-negative subpopulations in a human metastatic colon cancer cell line, SW620Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancerLiver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATH.Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal.Isolated hepatic perfusion for patients with liver metastases.Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRIChrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway.A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trialColorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases.Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody.FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotypingFool's gold, lost treasures, and the randomized clinical trial.Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsProvider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer.Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR studyPortal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastasesPhase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.Meta-analysis of outcomes of patients with stage IV colorectal cancer managed with chemotherapy/radiochemotherapy with and without primary tumor resection
P2860
Q24626790-A9A4F435-95C8-4FD8-A2B2-6FD3DFA5C61EQ26751018-DDDB6901-201E-4783-B567-055AD4CFBD17Q26775711-24942384-5625-4E1F-8D5C-60BCD5AFBEF5Q26782245-37312890-54AD-43E9-8AA4-DECEF9CBBBCBQ26859632-904E3571-70CD-4FF2-8857-3B44961EF144Q30422446-1961635F-7900-47FC-BCAB-A78EDC23A7E7Q30972278-55F0684F-9C7D-4512-8EFE-575CAE95DA78Q31115121-4E72DB5C-D969-44E1-A93D-E93881E4336EQ33396774-E4DFA231-69E8-423B-A786-99676EF1F8B7Q33406703-E68A52E7-A174-4A09-BBA8-2DD10CAE1782Q33414068-77FE9D76-6D10-4635-A482-999BB72BEFF9Q33558979-F0C7E0C3-FC62-418D-83CA-1E98EF342F46Q33813448-6A0CF2AD-738D-4102-8F20-66A7AF4CF68DQ33819683-D6D13F8F-7B54-4CE3-BC7E-55CDE667E998Q33906344-8587CC18-9B75-499B-BD3E-ECB57EF9E02DQ33937362-A993BDF9-BA96-4B57-9493-4095A08734EDQ33983663-A93BE6F4-1444-4FED-9583-C3ED2B2D3B60Q34048515-1CA2DE52-96B6-4996-8400-057B40EA5043Q34050521-1633F74E-E6C7-4A59-B5B8-88188F4815A9Q34108206-989A3B8E-1DB1-430A-AF11-FAC96F26F114Q34150655-A82263D0-9A56-4F89-BE24-722C170BEE47Q34206726-B6AFF961-C55E-44C6-A7A7-1A9723937A53Q34207776-9FBC6D53-86CE-4F1D-95D0-821C6AB25998Q34349053-6A530A2B-0AE7-4D0A-97D9-B565A55CAD02Q34360237-7AD49754-8505-49FC-B032-33DEFD2E1DBDQ34366871-56F2BE90-1686-4FA3-B6B3-E8B32A88764EQ34467133-7556288C-58C7-4784-ABF9-C4B1AB654928Q34529351-7D7F1536-DBE3-4607-B05C-AB27F484D72CQ34583743-8526CCD7-C072-4234-B93F-732697C65664Q34669260-E414E361-20C0-48D5-B9F7-67095043566AQ34716556-65BBD2BC-F570-479F-8D88-2A4FD1476901Q34734413-E95A3189-EF81-44B9-85C1-26FEEBA3325AQ35055207-7DF64BCC-5D31-4D8F-A0EF-52E90CB1D6F3Q35076251-256ABFC8-1661-4FA2-A360-D4B837A0A734Q35332617-72440BBD-0642-4D6F-A682-EE67264028D6Q35584825-110C92DB-9FB8-43EC-9348-3C567CDD41C6Q36063355-82754AE0-AE51-485B-A888-901D87AE5AD9Q36083102-72FCF6CB-F5BA-414E-AACE-FB448CC15FDEQ36105171-CA91DB83-B675-48D6-BA3A-D469B6B9C5CEQ36206186-1A2B79AF-7B0E-4A32-BC07-1C6F356F0863
P2860
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Five-year data and prognostic ...... anced colorectal cancer: N9741
@ast
Five-year data and prognostic ...... anced colorectal cancer: N9741
@en
type
label
Five-year data and prognostic ...... anced colorectal cancer: N9741
@ast
Five-year data and prognostic ...... anced colorectal cancer: N9741
@en
prefLabel
Five-year data and prognostic ...... anced colorectal cancer: N9741
@ast
Five-year data and prognostic ...... anced colorectal cancer: N9741
@en
P2093
P2860
P356
P1476
Five-year data and prognostic ...... anced colorectal cancer: N9741
@en
P2093
Brian P Findlay
Hanna K Sanoff
Henry C Pitot
Megan E Campbell
Ramesh K Ramanathan
Richard M Goldberg
Roscoe F Morton
Stephen K Williamson
P2860
P304
P356
10.1200/JCO.2008.17.7147
P407
P577
2008-11-10T00:00:00Z